[Current Diagnostics and Therapy Recommendations for Ocular Basal Cell Carcinoma]

Overview

Journal Ophthalmologe

Specialty Ophthalmology

Date 2016 Oct 19

PMID 27752782

Citations 11

Authors

V Kakkassery

K U Loeffler

M Sand

K R Koch

A M Lentzsch

A C Nick

I A Adamietz

L M Heindl

Affiliations

Soon will be listed here.

Abstract

The treatment options for basal cell carcinoma (BCC) have recently been augmented with the introduction of novel chemotherapeutic drugs. New S2 guidelines on the disease have also been published. The aim of this article is to present a comprehensive state of the art description of the features of ocular BCC and an overview of the various therapeutic options. Particular emphasis is placed on the clinical signs, the diagnostic tools to identify periocular BCC and interpretation of the different histopathological subtypes. Tumor staging, TNM classification, interdisciplinary tumor conference reviews as well as psycho-oncological services play an important role in patients with pronounced periocular BCC. Surgical removal with a histological R0 resection is an important component of therapy options in this disease and includes the microsurgical excision into healthy tissue and the subsequent covering of the defect. A special focus of this article is the treatment of locally extensive and metastasized BCC.

Citing Articles

Surgical excision of eyelid tumors and subsequent ophthalmoplastic reconstruction.

Gaca P, Rejdak R, Lewandowicz M, Kopecky A, Kakkassery V, Heindl L Ophthalmologie. 2023; 121(Suppl 1):23-32.

PMID: 37989962 DOI: 10.1007/s00347-023-01956-9.

[Recurrence risk of periocular basal cell carcinoma after histologically controlled excision].

Dethmers A, Low U, Langenbucher A, Flockerzi F, Bohle R, Seitz B Ophthalmologie. 2022; 120(3):285-293.

PMID: 36112203 DOI: 10.1007/s00347-022-01719-y.

Effective systemic treatment of advanced periocular basal cell carcinoma with sonidegib.

Rokohl A, Heindl L Graefes Arch Clin Exp Ophthalmol. 2021; 259(12):3821-3822.

PMID: 34338845 PMC: 8589764. DOI: 10.1007/s00417-021-05311-z.

[Occult basal cell carcinoma intermingling with seborrheic keratosis of the eyelid : A clinicopathological case report].

Nuessle S, Lang S, Auw-Haedrich C Ophthalmologie. 2021; 119(6):636-638.

PMID: 34043084 DOI: 10.1007/s00347-021-01407-3.

Effective treatment of locally advanced periocular basal cell carcinoma with oral hedgehog pathway inhibitor?.

Hou X, Rokohl A, Ortmann M, Heindl L Graefes Arch Clin Exp Ophthalmol. 2020; 258(10):2335-2337.

PMID: 32514773 PMC: 7550312. DOI: 10.1007/s00417-020-04779-5.

References

Engelmann V, Pfrommer S, Dridi M, Piening J, Lohmann C, Merte R . [Comparison of the aesthetic outcome and complication rate of reconstructive surgical procedures of the eyelid after basalioma excision]. Ophthalmologe. 2010; 108(1):33-7. DOI: 10.1007/s00347-010-2212-x. View

Griep C, Davelaar J, Scholten A, Chin A, Leer J . Electron beam therapy is not inferior to superficial x-ray therapy in the treatment of skin carcinoma. Int J Radiat Oncol Biol Phys. 1995; 32(5):1347-50. DOI: 10.1016/0360-3016(94)00603-I. View

Cho M, Gordon L, Rembielak A, Woo T . Utility of radiotherapy for treatment of basal cell carcinoma: a review. Br J Dermatol. 2014; 171(5):968-73. DOI: 10.1111/bjd.13253. View

LoRusso P, Rudin C, Reddy J, Tibes R, Weiss G, Borad M . Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin Cancer Res. 2011; 17(8):2502-11. PMC: 5244484. DOI: 10.1158/1078-0432.CCR-10-2745. View

Zhang H, Ping X, Lee P, Wu X, Yao Y, Zhang M . Role of PTCH and p53 genes in early-onset basal cell carcinoma. Am J Pathol. 2001; 158(2):381-5. PMC: 1850308. DOI: 10.1016/S0002-9440(10)63980-6. View

Singer S, Danker H, Briest S, Dietrich A, Dietz A, Einenkel J . Effect of a structured psycho-oncological screening and treatment model on mental health in cancer patients (STEPPED CARE): study protocol for a cluster randomized controlled trial. Trials. 2014; 15:482. PMC: 4295289. DOI: 10.1186/1745-6215-15-482. View

Zeissig S, Singer S, Koch L, Blettner M, Arndt V . [Utilisation of Psycho-oncological Services in Hospitals and Outpatient Counselling Centres by Survivors of Breast, Colon and Prostate Cancer]. Psychother Psychosom Med Psychol. 2014; 65(5):177-82. DOI: 10.1055/s-0034-1395627. View

Rubin A, Chen E, Ratner D . Basal-cell carcinoma. N Engl J Med. 2005; 353(21):2262-9. DOI: 10.1056/NEJMra044151. View

Ozgur O, Yin V, Chou E, Ball S, Kies M, William W . Hedgehog Pathway Inhibition for Locally Advanced Periocular Basal Cell Carcinoma and Basal Cell Nevus Syndrome. Am J Ophthalmol. 2015; 160(2):220-227.e2. DOI: 10.1016/j.ajo.2015.04.040. View

10.

Papastefanou V, Rene C . Secondary Resistance to Vismodegib After Initial Successful Treatment of Extensive Recurrent Periocular Basal Cell Carcinoma with Orbital Invasion. Ophthalmic Plast Reconstr Surg. 2015; 33(3S Suppl 1):S68-S70. DOI: 10.1097/IOP.0000000000000565. View

11.

Sand M, Bechara F, Gambichler T, Sand D, Friedlander M, Bromba M . Next-generation sequencing of the basal cell carcinoma miRNome and a description of novel microRNA candidates under neoadjuvant vismodegib therapy: an integrative molecular and surgical case study. Ann Oncol. 2015; 27(2):332-8. DOI: 10.1093/annonc/mdv551. View

12.

Hishmi A, Koch K, Matthaei M, Bolke E, Cursiefen C, Heindl L . Modified Hughes procedure for reconstruction of large full-thickness lower eyelid defects following tumor resection. Eur J Med Res. 2016; 21(1):27. PMC: 4929749. DOI: 10.1186/s40001-016-0221-1. View

13.

Gilbody J, Aitken J, Green A . What causes basal cell carcinoma to be the commonest cancer?. Aust J Public Health. 1994; 18(2):218-21. DOI: 10.1111/j.1753-6405.1994.tb00231.x. View

14.

Ling G, Ahmadian A, Persson A, Unden A, Afink G, Williams C . PATCHED and p53 gene alterations in sporadic and hereditary basal cell cancer. Oncogene. 2001; 20(53):7770-8. DOI: 10.1038/sj.onc.1204946. View

15.

Sommer F . [Eye lid tumours--clinical features, diagnosis and surgical treatment]. Klin Monbl Augenheilkd. 2008; 225(8):691-8. DOI: 10.1055/s-2008-1027486. View

16.

Marcil I, Stern R . Risk of developing a subsequent nonmelanoma skin cancer in patients with a history of nonmelanoma skin cancer: a critical review of the literature and meta-analysis. Arch Dermatol. 2000; 136(12):1524-30. DOI: 10.1001/archderm.136.12.1524. View

17.

Pfeiffer M . [Alternatives to lid reconstruction. Systematic presentation]. Ophthalmologe. 2004; 101(5):466-70. DOI: 10.1007/s00347-004-1006-4. View

18.

Tellechea O, Reis J, Domingues J, Baptista A . Monoclonal antibody Ber EP4 distinguishes basal-cell carcinoma from squamous-cell carcinoma of the skin. Am J Dermatopathol. 1993; 15(5):452-5. DOI: 10.1097/00000372-199310000-00007. View

19.

Gailani M, Leffell D, Glynn M, Zaphiropoulos P, Pressman C, Unden A . The role of the human homologue of Drosophila patched in sporadic basal cell carcinomas. Nat Genet. 1996; 14(1):78-81. DOI: 10.1038/ng0996-78. View

20.

Alter M, Hillen U, Leiter U, Sachse M, Gutzmer R . Current diagnosis and treatment of basal cell carcinoma. J Dtsch Dermatol Ges. 2016; 13(9):863-74. DOI: 10.1111/ddg.12798. View